Agios Pharmaceuticals (NASDAQ:AGIO) Releases Quarterly Earnings Results, Beats Estimates By $0.12 EPS

Key Points

• Agios reported adjusted EPS of ($1.69), beating estimates by $0.12, and revenue of $20.75 million versus expectations of $13.91 million, a 137.7% year‑over‑year increase.
• The U.S. launch of mitapivat (AQVESME) is off to a strong start with $20.7M in Q1 net revenues and 242 prescriptions, and management plans to submit an sNDA for sickle cell disease in Q2 under the Accelerated Approval pathway with a confirmed trial design.
• Agios ended Q1 with over $1 billion in cash, equivalents and marketable securities and expects 2026 operating expenses to be roughly flat versus 2025, while several near‑term pipeline catalysts (tebapivat and AG‑236 data in 2026) could drive upside.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, topping analysts' consensus estimates of ($1.81) by $0.12, FiscalAI reports. The business had revenue of $20.75 million during the quarter, compared to analysts' expectations of $13.91 million. Agios Pharmaceuticals had a negative return on equity of 31.07% and a negative net margin of 764.01%.The firm's quarterly revenue was up 137.7% on a year-over-year basis.

Here are the key takeaways from Agios Pharmaceuticals' conference call:

• AQVESME U.S. launch off to a strong start with $20.7M in Q1 mitapivat net revenues (US $18.8M) and 242 prescriptions by REMS‑certified physicians as of March 31, though management cautioned early prescriptions reflect highly motivated patients and average initiation timelines are expected to normalize to ~10–12 weeks.
• Agios plans to submit an sNDA for mitapivat in sickle cell disease in Q2 under the U.S. Accelerated Approval pathway after productive pre‑sNDA discussions with the FDA and alignment on a confirmatory trial design.
• Multiple near‑term pipeline catalysts could drive upside, including phase II‑B tebapivat top‑line data in lower‑risk MDS (H1 2026), phase II tebapivat data in sickle cell disease (H2 2026), and early healthy volunteer data for AG‑236 (H1 2026).
• Financial position and discipline support execution — operating expense guidance for 2026 is expected to be approximately flat versus 2025, while the company ended Q1 with over $1 billion in cash, equivalents and marketable securities to fund launches and development.

Agios Pharmaceuticals Trading Up 13.1%

NASDAQ:AGIO opened at $28.05 on Thursday. Agios Pharmaceuticals has a 12-month low of $22.24 and a 12-month high of $46.00. The firm has a market cap of $1.67 billion, a PE ratio of -3.95 and a beta of 0.79. The stock has a fifty day moving average price of $29.88 and a 200 day moving average price of $31.05.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Sunday, March 22nd. Bank of America lowered their target price on shares of Agios Pharmaceuticals from $44.00 to $41.00 and set a "buy" rating for the company in a research note on Tuesday, April 21st. The Goldman Sachs Group lifted their price target on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a "neutral" rating in a research report on Wednesday, April 1st. Weiss Ratings reissued a "sell (d)" rating on shares of Agios Pharmaceuticals in a research note on Friday, March 27th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Agios Pharmaceuticals from $31.00 to $36.00 and gave the stock a "neutral" rating in a report on Monday, April 6th. Six investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $41.78.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 2,940 shares of the stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total value of $102,047.40. Following the sale, the insider owned 80,277 shares of the company's stock, valued at $2,786,414.67. This trade represents a 3.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James William Burns sold 3,280 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total value of $113,848.80. Following the completion of the transaction, the insider owned 49,306 shares of the company's stock, valued at $1,711,411.26. The trade was a 6.24% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 15,582 shares of company stock worth $520,405 over the last quarter. 4.93% of the stock is currently owned by insiders.

Institutional Trading of Agios Pharmaceuticals

A number of institutional investors have recently bought and sold shares of AGIO. T. Rowe Price Investment Management Inc. acquired a new position in shares of Agios Pharmaceuticals during the 4th quarter worth about $25,000. NewEdge Advisors LLC acquired a new stake in shares of Agios Pharmaceuticals during the 1st quarter worth about $40,000. Caitong International Asset Management Co. Ltd purchased a new stake in Agios Pharmaceuticals during the fourth quarter worth approximately $49,000. Quantbot Technologies LP purchased a new stake in Agios Pharmaceuticals during the third quarter worth approximately $79,000. Finally, Acadian Asset Management LLC acquired a new position in Agios Pharmaceuticals in the first quarter valued at approximately $133,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.